Single-agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), in small-cell lung cancer (SCLC) Meeting Abstract
| Authors: | Spigel, D.; Pietanza, M. C.; Bauer, T.; Ready, N.; Morgensztern, D.; Glisson, B. S.; Byers, L. A.; Johnson, M.; Burris, H.; Robert, F.; Han, T.; Bheddah, S.; Theiss, N.; Watson, S.; Mathur, D.; Vennapusa, B.; Strickland, D.; Zayed, H.; Dylla, S.; Peng, S.; Govindan, R.; Rudin, C. |
| Abstract Title: | Single-agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), in small-cell lung cancer (SCLC) |
| Meeting Title: | IASLC 17th World Conference on Lung Cancer |
| Keywords: | clinical trial; sclc; rovalpituzumab tesirine; delta-like protein 3 |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 12 |
| Issue: | 1 Suppl. |
| Meeting Dates: | 2016 Dec 4-7 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-01-01 |
| Start Page: | S260 |
| End Page: | S261 |
| Language: | English |
| ACCESSION: | WOS:000413055800240 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2016.11.252 |
| Notes: | Meeting Abstract: OA05.03 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work